H. Andersen

发表

Anxiety symptom severity and functional recovery or relapse.

Dan J Stein, D. Baldwin, O. Dolberg, 2009, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.

Escitalopram for the treatment of GAD: efficacy across different subgroups and outcomes.

D. Stein, W. Goodman, H. Andersen, 2005, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.

CLEP_A_199839 275..283

S. Sindrup, R. Thomsen, H. Andersen, 2019 .

What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder?

D. Stein, D. Baldwin, O. Dolberg, 2006, The Journal of clinical psychiatry.

Effective dose of escitalopram in moderate versus severe DSM-IV major depression.

P. Bech, H. Andersen, A. Wade, 2006, Pharmacopsychiatry.

Improvement of Quality of Life in Panic Disorder with Escitalopram, Citalopram, or Placebo

Dan J Stein, D. Baldwin, O. Dolberg, 2007, Pharmacopsychiatry.

Baseline severity of depression predicts antidepressant drug response relative to escitalopram.

C. Kilts, T. Schlaepfer, H. Andersen, 2009, Expert opinion on pharmacotherapy.

Impact of escitalopram treatment on Quality of Life Enjoyment and Satisfaction Questionnaire scores in major depressive disorder and generalized anxiety disorder

K. Demyttenaere, H. Andersen, E. Reines, 2008, International clinical psychopharmacology.

Citalopram dose-response revisited using an alternative psychometric approach to evaluate clinical effects of four fixed citalopram doses compared to placebo in patients with major depression

P. Bech, P. Tanghøj, K. Overø, 2002, Psychopharmacology.

A randomized, double-blind, 24‐week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder*

L. Colonna, H. Andersen, E. Reines, 2005, Current medical research and opinion.

Escitalopram versus venlafaxine XR in the treatment of depression

S. Montgomery, H. Andersen, 2006, International clinical psychopharmacology.

Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis.

R. Lam, S. Kennedy, H. Andersen, 2006, Journal of psychiatry & neuroscience : JPN.

Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder

Alan Wade, U. Lepola, Ulla Lepola, 2004, International clinical psychopharmacology.

Escitalopram in the treatment of major depressive disorder: A meta-analysis

M. Thase, S. Kennedy, H. Andersen, 2009 .

Escitalopram in the treatment of major depressive disorder: a meta-analysis.

M. Thase, S. Kennedy, H. Andersen, 2009, Current medical research and opinion.

Baseline severity of depression predicts antidepressant drug response relative to escitalopram

C. Kilts, T. Schlaepfer, H. Andersen, 2009 .

Clinical milestones predict symptom remission over 6-month and choice of treatment of patients with major depressive disorder (MDD).

C. Kilts, T. Schlaepfer, H. Andersen, 2009, Journal of psychiatric research.

The effect of escitalopram on sleep problems in depressed patients

M. Lader, T. Bækdal, H. Andersen, 2005, Human psychopharmacology.

Escitalopram in the treatment of anxiety symptoms associated with depression

O. Dolberg, B. Bandelow, H. Andersen, 2007, Depression and anxiety.

Escitalopram dose-response revisited: an alternative psychometric approach to evaluate clinical effects of escitalopram compared to citalopram and placebo in patients with major depression.

P. Bech, A. Pedersen, P. Tanghøj, 2004, The international journal of neuropsychopharmacology.

Analysis of the Effect of Memantine in Reducing the Worsening of Clinical Symptoms in Patients with Moderate to Severe Alzheimer’s Disease

D. Wilkinson, H. Andersen, 2007, Dementia and Geriatric Cognitive Disorders.

Baselineseverityofdepression predictsantidepressantdrug responserelativetoescitalopram

C. Kilts, T. Schlaepfer, H. Andersen, 2009 .

The Influence of Baseline Severity on Efficacy of Escitalopram and Citalopram in the Treatment of Major Depressive Disorder: An Extended Analysis

R. Lam, H. Andersen, 2006, Pharmacopsychiatry.

Qualitative changes in symptomatology as an effect of treatment with escitalopram in generalized anxiety disorder and major depressive disorder

Y. Lecrubier, E. Weiller, O. Dolberg, 2008, European Archives of Psychiatry and Clinical Neuroscience.

Escitalopram Versus SNRI Antidepressants in the Acute Treatment of Major Depressive Disorder: Integrative Analysis of Four Double-Blind, Randomized Clinical Trials

S. Kornstein, G. Papakostas, Dayong Li, 2009, CNS Spectrums.

Escitalopram and duloxetine in the treatment of major depressive disorder: a pooled analysis of two trials

R. Lam, H. Andersen, A. Wade, 2008, International clinical psychopharmacology.

Impact of escitalopram treatment on Quality of Life Enjoyment and Satisfaction Questionnaire scores in major depressive disorder and generalized anxiety disorder

K. Demyttenaere, H. Andersen, E. Reines, 2008, International clinical psychopharmacology.